Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + atezolizumab
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + atezolizumab is a combination therapy consisting of cabozantinib, an oral small molecule tyrosine kinase inhibitor, and atezolizumab, a monoclonal antibody immune checkpoint inhibitor targeting PD-L1. This combination is being investigated for the treatment of various advanced solid tumors, including metastatic castration-resistant prostate cancer (mCRPC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC). Cabozantinib inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis—specifically MET, VEGFRs, and AXL—while also modulating the tumor microenvironment to promote an immune-permissive state. Atezolizumab blocks PD-L1 on tumor cells and immune cells to enhance T-cell–mediated antitumor responses. The combination has demonstrated synergistic clinical activity with improved progression-free survival compared to standard therapies in mCRPC and other cancers[1][3][5][6]. The safety profile is consistent with known effects of each agent.
- Brand names
- CabometyxCometriqTecentriq
- Other names
- cabotamig + atezolizumab
02
Targets
AXL (AXL receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TEK (Tie2)MET (Mesenchymal-epithelial transition factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on cabozantinib + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + atezolizumab.